| Literature DB >> 23763754 |
Shaofu Qiu1, Yong Wang, Xuebin Xu, Peng Li, Rongzhang Hao, Chaojie Yang, Nan Liu, Zhenjun Li, Zhongqiang Wang, Jian Wang, Zhihao Wu, Wenli Su, Guang Yang, Huiming Jin, Ligui Wang, Yansong Sun, Zhengan Yuan, Liuyu Huang, Hongbin Song.
Abstract
We identified 3 atypical Shigella flexneri varieties in China, including 92 strains with multidrug resistance, distinct pulse types, and a novel sequence type. Atypical varieties were prevalent mainly in developed regions, and 1 variant has become the dominant Shigella spp. serotype in China. Improved surveillance will help guide the prevention and control of shigellosis.Entities:
Keywords: China; Shigella flexneri; antimicrobial resistance; atypical; bacteria; diarrheal disease; enteric infections; gram-negative bacteria; multidrug resistance; pulse type; sequence type; shigellosis; variants
Mesh:
Substances:
Year: 2013 PMID: 23763754 PMCID: PMC3713959 DOI: 10.3201/eid1907.111221
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Distribution of different Shigella spp. in China during 2008–2010 and 1991–2000
| Serotype | 1991–2000* | May 2008–December 2010 | |
|---|---|---|---|
| No. (%) isolates | No. (%) isolates | ||
|
| 8,082 (86.2) | 208 (76.2) | |
| 1a | 272 (2.9) | 9 (3.3) | |
| 1b | 325 (3.5) | 29 (10.6) | |
| 1c | 15 (0.2) | 0 | |
| 2a | 6,468 (69.0) | 64 (23.4) | |
| 2b | 152 (1.6) | 3 (1.1) | |
| 3a | 255 (2.7) | 0 | |
| 3b | 57 (0.6) | 0 | |
| 3c | 9 (0.1) | 0 | |
| 4 | 230 (2.5) | 0 | |
| 5 | 30 (0.3) | 1 (0.4) | |
| 6 | 73 (0.8) | 3 (1.1) | |
| x | 70 (0.7) | 5 (1.8) | |
| y | 126 (1.3) | 2 (0.7) | |
| X variant (−:7,8, E1037), indole-negative variety | 0 |
| 73 (26.7) |
| 0 |
| 17 (6.2) | |
| 0 |
| 2 (0.7) | |
|
| 1,022 (10.9) |
| 56 (20.5) |
|
| 132 (1.4) |
| 6 (2.2) |
|
| 139 (1.5) | 3 (1.1) |
*Data are from ().
Antimicrobial drug resistance profiles of variant serotypes of Shigella flexneri isolates recovered from patients with diarrhea, China, May 2008–December 2010*
| Antimicrobial drug | % Resistant isolates | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X variant (−:7,8, E1037), indole-negative variety, n = 73 | Serotype 2 variant (II:3,4,7,8), n = 17 | Untypeable variant (−:E1037), n = 2 | |||||||||||||
| R | I | S | R | I | S | R | I | S | |||||||
| Ampicillin | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
| Ampicillin/sulbactam | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
| Chloramphenicol | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
| Nalidixic acid | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
| Tetracycline | 100.0 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | 0 | 0 | ||||||
| Amoxicillin/clavulanic acid | 91.8 | 5.5 | 2.7 | 88.2 | 0 | 11.8 | 100.0 | 0 | 0 | ||||||
| Trimethoprim/sulfa | 90.4 | 0 | 9.6 | 58.8 | 0 | 41.2 | 100.0 | 0 | 0 | ||||||
| Norfloxacin | 82.2 | 16.4 | 1.4 | 29.4 | 0 | 70.6 | 100.0 | 0 | 0 | ||||||
| Ciprofloxacin | 39.7 | 49.3 | 11.0 | 29.4 | 0 | 70.6 | 100.0 | 0 | 0 | ||||||
| Levofloxacin | 21.9 | 26.0 | 52.1 | 17.6 | 11.8 | 70.6 | 0 | 50.0 | 50.0 | ||||||
| Cefotaxime | 13.7 | 13.7 | 72.6 | 17.6 | 5.9 | 76.5 | 0 | 0 | 100.0 | ||||||
| Gentamicin | 6.8 | 0 | 93.2 | 5.9 | 0 | 94.1 | 0 | 0 | 100.0 | ||||||
| Ceftazidime | 5.5 | 2.7 | 91.8 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | ||||||
| Imipenem | 2.7 | 0 | 97.3 | 0 | 0 | 100.0 | 0 | 0 | 100.0 | ||||||
*R, resistant; I, intermediate; S, susceptible.